你即將離開本站

並前往https://cen.acs.org/pharmaceuticals/drug-development/GSK-Novo-Nordisk-expand-investments/99/i43

GSK and Novo Nordisk expand investments in RNAi - C&EN

... company Arrowhead Pharmaceuticals to develop an siRNA therapy for nonalcoholic steatohepatitis (NASH), a form of fatty liver disease.

確定！ 回上一頁

查詢 「steatohepatitis中文」的人也找了：

  1. Steatohepatitis
    2.
  2. steatosis中文
    3.
  3. parenchymal liver disease中文
    4.
  4. nash肝炎
    5.
  5. 脂肪肝分級
    6.
  6. 脂肪肝等級
    7.
  7. NAFLD
    8.
  8. fatty infiltration中文
    9.